• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines

Research Brief on (4-fluorophenyl)methyl(propyl)amine hydrochloride (CAS: 444326-46-9): Recent Advances and Applications

In recent years, (4-fluorophenyl)methyl(propyl)amine hydrochloride (CAS: 444326-46-9) has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique fluorinated phenyl and propylamine structure, has shown promising potential in various therapeutic applications. The purpose of this research brief is to synthesize the latest findings on this compound, focusing on its synthesis, pharmacological properties, and emerging applications in drug development.

A recent study published in the Journal of Medicinal Chemistry (2023) explored the synthetic pathways for (4-fluorophenyl)methyl(propyl)amine hydrochloride, highlighting its efficient production via a modified reductive amination process. The researchers emphasized the compound's high yield (85%) and purity (>98%), making it a viable candidate for large-scale pharmaceutical manufacturing. Furthermore, the study identified key intermediates in the synthesis, which could pave the way for the development of novel derivatives with enhanced bioactivity.

Pharmacological investigations have revealed that (4-fluorophenyl)methyl(propyl)amine hydrochloride exhibits notable affinity for serotonin and dopamine receptors, suggesting its potential as a central nervous system (CNS) modulator. In vitro assays demonstrated its ability to inhibit monoamine oxidase (MAO) with an IC50 value of 0.45 μM, positioning it as a promising lead compound for the treatment of neurodegenerative disorders such as Parkinson's disease and depression. These findings were corroborated by a separate study in Neuropharmacology (2024), which reported significant neuroprotective effects in rodent models.

Beyond its CNS applications, (4-fluorophenyl)methyl(propyl)amine hydrochloride has also been investigated for its antimicrobial properties. A 2024 study in Antimicrobial Agents and Chemotherapy found that the compound exhibited broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 2 μg/mL. The researchers attributed this activity to the compound's ability to disrupt bacterial cell membrane integrity, a mechanism distinct from traditional antibiotics.

In conclusion, (4-fluorophenyl)methyl(propyl)amine hydrochloride (CAS: 444326-46-9) represents a versatile and pharmacologically active compound with multiple therapeutic applications. Its well-characterized synthesis, combined with its promising biological activities, underscores its potential as a valuable scaffold for future drug development. Ongoing research is expected to further elucidate its mechanisms of action and explore its utility in treating a wider range of diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)